These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 26157112

  • 1. Comment on: Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.
    Kirby A.
    J Antimicrob Chemother; 2015 Nov; 70(11):3170. PubMed ID: 26157112
    [No Abstract] [Full Text] [Related]

  • 2. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data-authors' response.
    Zhanel GG, Wolter KD, Karlowsky JA.
    J Antimicrob Chemother; 2015 Nov; 70(11):3170-1. PubMed ID: 26242414
    [No Abstract] [Full Text] [Related]

  • 3. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.
    Zhanel GG, Wolter KD, Calciu C, Hogan P, Low DE, Weiss K, Karlowsky JA.
    J Antimicrob Chemother; 2014 Oct; 69(10):2835-40. PubMed ID: 24920652
    [Abstract] [Full Text] [Related]

  • 4. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ, Zhanel GG.
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [Abstract] [Full Text] [Related]

  • 5. [Discussions on PRSP and BLNAR].
    Tajima T, Meguro H, Akita H, Iwata T.
    Jpn J Antibiot; 2001 May; 54 Suppl B():103; discussion 104-6. PubMed ID: 12638161
    [No Abstract] [Full Text] [Related]

  • 6. Azithromycin and lower respiratory tract infections.
    Blasi F, Cazzola M, Tarsia P, Cosentini R, Aliberti S, Santus P, Allegra L.
    Expert Opin Pharmacother; 2005 Oct; 6(13):2335-51. PubMed ID: 16218893
    [Abstract] [Full Text] [Related]

  • 7. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H, Liu YL, Chen MJ, Xu YC, Sun HL, Yang QW, Hu YJ, Cao B, Chu YZ, Liu Y, Zhang R, Yu YS, Sun ZY, Zhuo C, Ni YX, Hu BJ.
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [Abstract] [Full Text] [Related]

  • 8. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from patients in primary hospitals in Shanghai from 2007 to 2010].
    Zhou CM, Hu BJ, Gao XD, Bao R, Xie HM, Huang SL, Tao LL, He LX.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 May; 36(5):346-50. PubMed ID: 24047808
    [Abstract] [Full Text] [Related]

  • 9. The continuing challenge of lower respiratory tract infections.
    Moellering RC.
    Clin Infect Dis; 2004 May 15; 38 Suppl 4():S319-21. PubMed ID: 15127364
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Microbiological evaluation of antibiotics for empirical therapy of community-acquired infections of the lower respiratory tract].
    Bogdanov MB, Chernen'kaia TV.
    Antibiot Khimioter; 2000 May 15; 45(10):15-8. PubMed ID: 11212394
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
    Rapp RP.
    Postgrad Med; 2002 Sep 15; 112(3 Suppl):12-7. PubMed ID: 19667590
    [Abstract] [Full Text] [Related]

  • 15. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M.
    J Antimicrob Chemother; 2003 Apr 15; 51(4):947-55. PubMed ID: 12654763
    [Abstract] [Full Text] [Related]

  • 16. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
    Pell DM.
    Postgrad Med; 2002 Sep 15; 112(3 Suppl):5-6. PubMed ID: 19667592
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL.
    Postgrad Med; 2002 Sep 15; 112(3 Suppl):18-25. PubMed ID: 19667591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.